VLVbio was established in 2013 in Stockholm, Sweden, having been granted exclusive rights to a unique apoptosis marker for keratin 18 (K18) expressing cells of human epithelial origin. Continuously, we strive to acquire and develop novel intellectual property from the academic research and healthcare market for the detection and quantification of different forms of cells death in normal or pathophysiological circumstances.

We develop, market and sell products to global distributors, clinics, research institutions, universities and to the pharmaceutical industry, all operating within fields such as hepatology, toxicology and oncology.

Our biomarker and antibody assays, based on our unique antibodies, enable the measurement and detection of apoptosis and total cell death in human samples, providing a deeper understanding about cell death mechanisms.